Imunon, Inc. (NASDAQ:IMNN – Free Report) – Brookline Capital Markets increased their Q2 2026 earnings per share estimates for Imunon in a report released on Friday, June 5th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.68) for the quarter, up from their prior estimate of ($0.69). The consensus estimate for Imunon’s current full-year earnings is ($3.69) per share. Brookline Capital Markets also issued estimates for Imunon’s Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($3.00) EPS and FY2027 earnings at ($3.11) EPS.
Several other research firms also recently issued reports on IMNN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Imunon in a research note on Tuesday, April 21st. Maxim Group set a $10.00 price target on Imunon and gave the stock a “buy” rating in a research note on Friday, April 17th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.
Imunon Trading Up 0.5%
NASDAQ IMNN opened at $2.02 on Wednesday. The company’s fifty day simple moving average is $2.65 and its 200-day simple moving average is $3.19. Imunon has a 52 week low of $1.95 and a 52 week high of $27.65. The stock has a market cap of $8.48 million, a P/E ratio of -0.39 and a beta of 1.95.
Imunon (NASDAQ:IMNN – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.38.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. Riverview Capital Advisers LLC grew its holdings in Imunon by 193.3% during the 3rd quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock worth $176,000 after acquiring an additional 22,649 shares in the last quarter. DRW Securities LLC raised its stake in shares of Imunon by 6.9% in the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock valued at $224,000 after purchasing an additional 3,803 shares in the last quarter. Finally, Armistice Capital LLC bought a new position in shares of Imunon during the fourth quarter worth about $1,017,000. 4.47% of the stock is currently owned by institutional investors.
Imunon Company Profile
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
Featured Articles
- Five stocks we like better than Imunon
- Optical Cable Corporation: Strong Earnings, But Hurdles Remain
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
